article Open AccessTop 1% cited

Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial

British Journal of Dermatology · 2016 · Vol. 175(5) · pp. 902–911

Robert Bissonnette(Innovaderm (Canada))Kim Papp(Probity Medical Research)Yves Poulin(Centre de Recherche Dermatologique du Québec Métropolitain)Melinda Gooderham(Probity Medical Research)Maitreyi Raman(Probity Medical Research)Lotus Mallbris(Pfizer (United States))C. Wang(Pfizer (United States))Vivek S. Purohit(Pfizer (United States))Carla Mamolo(Pfizer (United States))Jocelyne Papacharalambous(Pfizer (United States))W.C. Ports✉(Pfizer (United States))

View via DOI Publisher page

Abstract

Tofacitinib ointment showed significantly greater efficacy vs. vehicle across end points, with early onset of effect and comparable safety/local tolerability to vehicle. JAK inhibition through topical delivery is potentially a promising therapeutic target for AD.

Dermatology and Skin Diseases Allergic Rhinitis and Sensitization Asthma and respiratory diseasesTofacitinibEczema Area and Severity IndexTolerabilityMedicineJanus kinase inhibitorAtopic dermatitisAdverse effectRandomized controlled trialClinical endpointInternal medicine

MeSH terms

AdolescentAdultDermatitis, AtopicDouble-Blind MethodDrug Administration ScheduleFemaleHumansMaleMiddle AgedOintmentsPiperidinesPyrimidinesPyrrolesTreatment OutcomeProtein Kinase Inhibitors